PRFXPRFXUtilities · Drug Manufacturers - Specialty & Generic

PRFX Stock Forecast: PRF Technologies Ltd. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.48

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 4 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$1.7M
Ticker Nerd rank
4/ 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$7.3M
Net income−$7.3M
Free cash flow−$5.0M
Quarterly, 7 quarters to 30 June 2024 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores PRF Technologies Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
4/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
27
Momentum
21
Revisions
20
Issuance
20
Volatility
2
Quality
1
Value
0
Growth
0

Accruals (27): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (0): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PRFX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PRFX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Oct 2024Maxim GroupDowngradeHold—
26 June 2024Maxim GroupReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

PRFX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

PRFX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
53.7×

Cheaper than 4% of US stocks

Price / book
0.1×

Cheaper than 96% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−45.3%

Higher than 23% of US stocks

Return on assets
−21.9%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • PRF Technologies Ltd. has a market value of $1.7M.

  • Revenue in the twelve months to 30 June 2024: $0.0.

  • Net income over the same four quarters: −$17.7M.

  • Free cash flow in the twelve months to 30 June 2024: −$11.4M, after $21K of capital spending.

  • Shares outstanding: 402,628.

  • PRF Technologies Ltd. employs 6 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2024 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

PRFX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
PRFXPRF Technologies Ltd.$1.7M4
SXTCChina Sxt Pharmaceuticals, Inc.$1.8M7
SBFMSunshine Biopharma, Inc.$1.8M34
GELSGelteq Ltd.$2.9M10
APUSApimeds Pharmaceuticals US, Inc.$3.0M11
IMCCIM Cannabis Corp.$921,900.0024
SNOASonoma Pharmaceuticals, Inc.$3.7M21

Take a look at PRFX’s peer groups, ranked by the model: utility stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own PRF Technologies Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about PRFX

How does Ticker Nerd's model rank PRFX?

As at 21 Nov 2026, PRF Technologies Ltd. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (27 of 100).

What is the PRFX stock forecast for 2030?

No analyst covering PRF Technologies Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRFX are extrapolating price history, which says nothing about the business.

What does PRF Technologies Ltd. do?

PRF Technologies Ltd. is a specialty pharmaceutical company focused on reformulating established therapeutics for clinical use. Its current portfolio centers on post-surgical pain management and localized drug-delivery solutions, including PRF-110, an oil-based formulation designed for direct application into the surgical wound bed to provide sustained analgesia, and OcuRing-K, a bio-erodible implant developed for use in cataract surgery.

Company

About PRF Technologies Ltd.

PRF Technologies Ltd. is a specialty pharmaceutical company focused on reformulating established therapeutics for clinical use. Its current portfolio centers on post-surgical pain management and localized drug-delivery solutions, including PRF-110, an oil-based formulation designed for direct application into the surgical wound bed to provide sustained analgesia, and OcuRing-K, a bio-erodible implant developed for use in cataract surgery. The company operates in the healthcare sector with an emphasis on developing proprietary treatment options that target specific surgical settings and recovery needs. Headquartered in Tel Aviv, Israel, PRF Technologies also maintains activity in advanced drug-delivery technologies, supporting its role as a niche player in specialty therapeutics and perioperative care.

CEO Mr. Efraim Cohen-Arazi · 6 employees · Israel · https://www.painreform.com